Anti-HLA class I (HLA-A,B,C) antibody

Purpose

Immune checkpoint inhibitors and cancer vaccines are currently attracting a lot of attention as novel cancer treatment strategies. In order to achieve sufficient anti-tumor effects using these treatments, target tumor cells need to express HLA class I antigens. It is important to evaluate the expression of HLA class I antigens in tumor cells in order to establish treatment methods. This product is an antibody that recognizes human HLA-A,B,C. Because it can be used for immunostaining, it is useful for evaluating the expression of HLA class I in tumor cells and tissues.

Anti-HLA class I (HLA-A,B,C) (Human) mAb (Clone EMR8-5)

Commonly used clone which has many citations
The product can be used for various applications

Application data

Western Blotting

Analysis of reactivity using recombinant MHC class I heavy chain extracellular domain

Analysis of HLA class I expression in oral cavity cancer cell line, OSC20

  Lane 1: Oral cavity cancer cell line OSC20
  Lane 2: OSC20-A*24:02 (HLA-A*24:02 transfectant)
  Lane 3: K562
  Lane 4: Recombinant HLA-A*24:02
  Data was kindly provided by Dr. Toshihiko Torigoe
  (The Department of Pathology, Sapporo Medical University School of Medicine).

Flow cytometry

See detail

Anti-HLA class I (HLA-A,B,C) (Human) mAb (Clone EMR8-5.1)

The best clone for immunohistochemistry
The product is ready to use

Application data

Immunohistochemistry (fluorescent staining manual method)

HLA class I expression is observed in stromal cells, normal epithelial cells, infiltrating lymphocytes and macrophages. However, it is hardly observed on cancer cells (cytokeratin positive). HLA-DR is expressed on monocytes and macrophages.

Tissue：Head and neck cancer
Orange：HLA class I (Code No. D370-3H)
Red：HLA-DR (clone LN-3)
Blue：Cytokeratin (clone AE1/AE3)
Data was kindly provided by Dr. Susumu Suzuki (Aichi Medical University of Medicine).